Coup for AstraZeneca after key lung cancer drug made available on NHS : telegraph

As it stated in telegraph

Coup for AstraZeneca after key lung cancer drug made available on NHS

Coup for AstraZeneca after key lung cancer drug made available on NHS

AstraZeneca has won a major victory in the UK after the country's drugs watchdog approved one of the most important cancer drugs in its oncology portfolio.The National Institute for Health and Care Excellent (Nice) announced this morning that osimertinib, known under the brand name Tagrisso, will be made available to people with a certain type of lung cancer through the Cancer Drugs Fund (CDF)."This is a really important announcement for us," said Lisa Anson, country president for AstraZeneca in the UK and Ireland."Tagrisso is a critical medicine in the AstrZeneca portfolio and a breakthrough precision medicine.


moreover from theguardian

'Breakthrough' lung cancer drug made available on NHS

'Breakthrough' lung cancer drug made available on NHS

A last-chance drug that can lead to an "unprecedented" reduction in lung cancer tumours has become available on the NHS.Tagrisso (osimertinib) was granted a licence only in February and has been hailed as a breakthrough drug by manufacturer AstraZeneca.The once-a-day tablet will be available immediately for patients with non-small-cell lung cancer who have a specific mutation, known as EGFR T790M-positive, that means they have stopped responding to earlier treatments.Experts predict about 300 patients in England and Wales will be eligible for Tagrisso every year.


coupled with nice

NICE recommends new drug osimertinib for hundreds of people with lung cancer

NICE recommends new drug osimertinib for hundreds of people with lung cancer

Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as Tagrisso, after NICE says it should be made available on the Cancer Drugs Fund (CDF).Osimertinib which was only licensed in February this year is recommended in draft guidance to treat a particularly aggressive form of lung cancer.Earlier this year, NICE said reforms to the CDF would help deliver faster access to effective cancer treatments.Osimertinib is the first drug to benefit from the new arrangements.